Search Results

TheraPeak® T-VIVO®

TheraPEAK® T-VIVO® Cell Culture Medium is a chemically-defined, non-animal origin (NAO) cell culture medium to culture and grow a variety of hematopoietic cells including:T cells: both dd (Gamma Delta) and aß (Alpha Beta) subpopulationsCAR-T...

TheraPro® CHO Media System

The TheraPRO® CHO Media System is a chemically defined, animal component-free formulation proven to optimize productivity and product quality when used in conjunction with the GS-CHO cell line.TheraPRO® CHO Media System is made of 4 components which...

Protocol for optimizing culture conditions for ex vivo activation during CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells

Long-range correction strategies require ex vivo activation of hematopoietic stem and progenitor cells (HSPCs) to engage the homology-directed repair (HDR) mechanism, but prolonged culture causes harmful cellular responses, reducing the long-term...

Authors: Della Volpe L, Vacca R, Di Micco R

SST Peer Reviewed

A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells

Ex vivo activation is a prerequisite to reaching adequate levels of gene editing by homology-directed repair (HDR) for hematopoietic stem and progenitor cell (HSPC)-based clinical applications. Here, we show that shortening culture time mitigates the...

Authors: Della Volpe L, Midena F, Vacca R, Tavella T, Alessandrini L, Farina G, Brandas C, Lo Furno E,...

SST Peer Reviewed

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

Precision gene editing in primary hematopoietic stem and progenitor cells (HSPCs) would facilitate both curative treatments for monogenic disorders as well as disease modelling. Precise efficiencies even with the CRISPR/Cas system, however, remain...

Authors: Cloarec-Ung FM, Beaulieu J, Suthananthan A, Lehnertz B, Sauvageau G, Sheppard HM, Knapp DJHF

SST Peer Reviewed

Engineering designer beta cells with a CRISPR-Cas9 conjugation platform

Genetically fusing protein domains to Cas9 has yielded several transformative technologies; however, the genetic modifications are limited to natural polypeptide chains at the Cas9 termini, which excludes a diverse array of molecules...

Authors: Lim D, Sreekanth V, Cox KJ, Law BK, Wagner BK, Karp JM

SST Peer Reviewed

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

Natural killer (NK) cells are an appealing off-the-shelf, allogeneic cellular therapy due to their cytotoxic profile. However, their activity against solid tumors remains suboptimal in part due to the upregulation of NK-inhibitory ligands, such as...

Authors: Shankar K, Zingler-Hoslet I, Tabima DM, Zima S, Shi L, Gimse K, Forsberg MH, Katta V, Davis SZ,...

SST Peer Reviewed

An efficient, non-viral arrayed CRISPR screening platform for iPSC-derived myeloid and microglia models

Here, we developed a CRISPR-Cas9 arrayed screen to investigate lipid handling pathways in human induced pluripotent stem cell (iPSC)- derived microglia.We established a robust method for the nucleofection of CRISPR-Cas9 ribonucleoprotein...

Authors: Meier S, Larsen ASG, Wanke F, Mercado N, Mei A, Takacs L, Mracsko ES, Collin L, Kampmann M,...

SST Peer Reviewed

BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism

Adoptive cell therapy (ACT) can address an unmet clinical need for patients with relapsed/refractory acute myeloid leukemia (AML), but its effect is often modest in the setting of high tumor burden. In this study, we postulated that strategies...

Authors: Saxena K, Ryu E, Hung SH, Singh S, Zhang Q, Zeng Z, Wang Z, Konopleva M, Yee C

SST Peer Reviewed

EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS

CD19 CART cell therapies have shown remarkable efficacy in non-Hodgkin lymphoma. However, durable response has been observed in less than half of treated patients due to epitope loss and T cell exhaustion. To overcome this limitation, we developed a...

Authors: A.Lawrence, S.Kleinsorge-Block, L.Jonart, P.Caimi, R.Parameswaran, J.Reese

SST Peer Reviewed

Data Type

Category

Research Area

Platform

Topic

Species

Characteristic

Format

Origin

TheraPeak® T-VIVO®

TheraPro® CHO Media System

Protocol for optimizing culture conditions for ex vivo activation during CRISPR-Cas9 gene editing in human hematopoietic stem and progenitor cells

A p38 MAPK-ROS axis fuels proliferation stress and DNA damage during CRISPR-Cas9 gene editing in hematopoietic stem and progenitor cells

Near-perfect precise on-target editing of human hematopoietic stem and progenitor cells

Engineering designer beta cells with a CRISPR-Cas9 conjugation platform

Virus-free CRISPR knockin of a chimeric antigen receptor into KLRC1 generates potent GD2-specific natural killer cells

An efficient, non-viral arrayed CRISPR screening platform for iPSC-derived myeloid and microglia models

BH3 mimetics augment cytotoxic T cell killing of acute myeloid leukemia via mitochondrial apoptotic mechanism

EFFICIENT COST-EFFECTIVE MANUFACTURE OF A NON-VIRAL TRANSPOSON BASED NOVEL BAFF-CART FOR TREATMENT OF B-CELL CANCERS